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patients using serum b-trace protein and
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Hospitals, Cambridge, UKResidual kidney function (RKF) contributes signiﬁcant
solute clearance in hemodialysis patients. Kidney Diseases
Outcomes Quality Initiative (KDOQI) guidelines suggest
that hemodialysis dose can be safely reduced in those with
residual urea clearance (KRU) of 2 ml/min/1.73 m2 or more.
However, serial measurement of RKF is cumbersome and
requires regular interdialytic urine collections. Simpler
methods for assessing RKF are needed. b-trace protein
(bTP) and b2-microglobulin (b2M) have been proposed
as alternative markers of RKF. We derived predictive
equations to estimate glomerular ﬁltration rate (GFR) and
KRU based on serum bTP and b2M from 191 hemodialysis
patients based on standard measurements of KRU and GFR
(mean of urea and creatinine clearances) using interdialytic
urine collections. These modeled equations were tested in
a separate validation cohort of 40 patients. A prediction
equation for GFR that includes both bTP and b2M provided
a better estimate than either alone and contained the
terms 1/bTP, 1/b2M, 1/serum creatinine, and a factor for
gender. The equation for KRU contained the terms 1/bTP,
1/b2M, and a factor for ethnicity. Mean bias between
predicted and measured GFR was 0.63 ml/min and
0.50 ml/min for KRU. There was substantial agreement
between predicted and measured KRU at a cut-off level
of 2ml/min/1.73m2. Thus, equations involvingbTP andb2M
provide reasonable estimates of RKF and could potentially
be used to identify those with KRU of 2 ml/min/1.73 m2
or more to follow the KDOQI incremental hemodialysis
algorithm.
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1090R esidual kidney function (RKF) is of signiﬁcant prog-nostic importance to patients on hemodialysis (HD).1 Ithas many clinical advantages including improved
nutrition,2 anemia, and phosphate control.3 Even small
amounts of RKF can provide signiﬁcant beneﬁt.
The Kidney Diseases Outcomes Quality Initiative
(KDOQI) suggests that minimum dialysis Kt/V targets may
be reduced in those with residual urea clearance (KRU)
$2 ml/min/1.73 m2. The European Best Practice Guidelines
(EBPG) recommend measuring RKF in HD patients using the
mean of urea and creatinine clearances and offer suggestions
to incorporate this into the HD prescription to allow indi-
vidual adjustment of dialysis prescription to meet minimum
dialysis adequacy targets.4,5 However, measurement of urea
and creatinine clearances requires an interdialytic urine
collection,6 which can be difﬁcult and inconvenient for
patients because RKF has to be monitored at least every 1 to 3
months for incremental HD to be practiced safely.7 Serum
biomarkers that obviate the need for regular urine collections
would be desirable.
Urea and creatinine are imperfect biomarkers of kidney
function because of external inﬂuences by factors such as
muscle mass, gender, diet, and nutritional status. Hence there
has been interest in novel alternative serum biomarkers,
especially cystatin C, b-trace protein (bTP), and b2-micro-
globulin (b2M).8–11 Use of cystatin C in dialysis patients is
limited because nonrenal clearance of cystatin C is signiﬁcant
and greatly exceeds its renal clearance in this setting.12,13 bTP
is a 23 kDa glycoprotein, also known as lipocalin type pros-
taglandin D synthase, and is expressed in a number of organs
including the brain, retina, testes, heart, and kidney.14 It is
virtually exclusively excreted by the kidneys,15 and serum
levels of bTP concentration correlate well with residual urine
volumes in HD patients,16 though its ability to predict RKF in
the HD setting has not been explored. b2-microglobulin
(b2M) has a molecular weight of 11.8 kDa and accumulates
in kidney failure. b2M levels have a close relationship with
RKF in HD17 and peritoneal dialysis.18,19 RKF is the most
signiﬁcant determinant of b2M levels in HD patients and has
a greater inﬂuence on these levels than the convective clear-
ance provided by hemodiaﬁltration (HDF).17,20
Hence bTP and b2M are promising candidates as
predictors of RKF in the HD setting. Both have limitationsKidney International (2016) 89, 1090–1098
J Wong et al.: Predicting residual kidney function c l i n i ca l i nves t iga t ionthough; b2M levels may increase with conditions such as
lupus and malignancy,21,22 and the clinical factors that
inﬂuence bTP are not well understood, although factors such
as gender,9 ethnicity,23 atherosclerosis,24 and inﬂammation9
have been implicated.
The aim of this study was to evaluate the usefulness of bTP
and b2M as estimates of RKF in HD patients. Clinical
determinants of bTP and b2M in the HD setting were explored,
and prediction equations to estimate residual urea clearance
(KRU) and glomerularﬁltration rate (GFR) inHDpatients were
constructed based on serum levels of bTP and b2M. The pre-
dictive equations were compared with KRU and GFR measured
using interdialytic urea and creatinine clearances in a separate
validation cohort of HD patients. We also explored the ability of
predictive equations to identify HD patients with KRU $2 ml/
min/1.73 m2 to follow the KDOQI incremental HD algorithm.
RESULTS
Characteristics of the study cohort
The study cohort consisted of 231 prevalent HD patients
based at the East & North Herts NHS Trust; 191 patients were
randomly selected into a modeling group for derivation of
equations for predicting parameters of RKF based on serum
levels of bTP and b2M, and the remaining 40 patients were
used for validation of the ﬁnal constructed equations
(Table 1). There were no signiﬁcant differences between the
modeling and validation cohorts in terms of age, anthropo-
metric parameters, ethnicity, blood pressure, dialysis
adequacy, diabetes prevalence, primary renal disease, and
Charlson co-morbidity index. Serum bTP and b2M concen-
trations were similar in both groups. The modeling cohort
had a higher GFR than the validation cohort (1.72 vs. 0.74 ml/
min/1.73 m2), whereas the validation cohort had a higher
prevalence of malignant disease and a higher median
C-reactive protein level.
Clinical determinants of bTP and b2M
Clinical determinants of serum bTP and b2M levels in HD
were sought using univariable and multivariable regression
analysis of clinical and demographic data from the modeling
cohort. Independent predictors of bTP and b2M are shown in
Table 2 and Table 3, respectively.
Predictors of bTP
In multivariable analysis, signiﬁcant positive associations with
bTP were found for male gender and the prevalence of ather-
omatous disease (Table 2). There were inverse associations for
age, body surface area, GFR, and treatment with HDF. Caucasian
ethnicity, prevalence of malignant disease, ultraﬁltration volume,
dialyzer Kt/V, diuretic use, and mean interdialytic weight gain
were associated with bTP in univariable analysis only.
Predictors of b2M
In multivariable analysis, signiﬁcant associations with b2M
were found with GFR and diabetic status (Table 3). Weight,
male gender, dialysis vintage, ultraﬁltration volume, meanKidney International (2016) 89, 1090–1098interdialytic weight gain, dialyzer Kt/V, and diuretic use were
associated in univariable analysis only. No signiﬁcant associ-
ations were found with C-reactive protein, HDF treatment, or
convective volume.
Development of prediction equations for KRU and GFR using
bTP and b2M
Linear regression models for KRU and GFR were determined
using the modeling cohort in three phases: (i) using bTP
alone, (ii) using b2M alone, and (iii) using both bTP and b2M.
Other relevant covariates were used in each case. The best
constructed models are shown in Table 4. Integrated
Discrimination Improvement analysis25 was used to assess the
predictive accuracy of the equation that incorporated both
bTP and b2M (model 3) compared with the best model using
a single biomarker (model 1 or 2) for cut-off levels 1 to
5 ml/min for both KRU and GFR. This demonstrated that
predictive equations that use both bTP and b2M had greater
accuracy than the best equation using a single protein (b2M)
at cut-off levels of measured clearance ranging from 1 to
5 ml/min. This was true for both estimated GFR and KRU. For
instance, at a cut-off KRU >2 ml/min/1.73 m2, the integrated
discrimination improvement index was 0.216 for the com-
bined equation compared with 0.171 for the equation using
b2M alone (P¼ 0.001). Likewise, at a cut-off GFR>2 ml/min/
1.73 m2 the corresponding values for the integrated discrim-
ination improvement index were 0.200 and 0.125 (P < 0.001).
The best modeled equation of GFR (Equation 1) explained
70% of the variance (R2 ¼ 0.70).
Estimated GFR ¼ 13:471
bTP
þ 52:379
b2M
þ 782:909
creatinine
þ 0:519 gender factor  3:939
Equation 1
Where for gender, male ¼ 1, female ¼ 0
The best model of KRU (Equation 2) explained 63% of the
variance (R2 ¼ 0.63).
Estimated KRU ¼ 9:097
bTP
þ 37:568
b2M
þ 0:402 ethnicity factor  2:049
Equation 2
Where for ethnicity, Caucasian ¼ 1, Non-Caucasian ¼ 0
Leave-out one-cross validation for estimated GFR and
KRU demonstrated a pseudo-R2 of 0.66 and 0.60, respectively,
which were similar to the performance of the above regression
equations in the modeling cohort (R2 ¼ 0.70 and 0.63,
respectively).
Evaluation of predictive equations
The best modeled predictive equations for estimating KRU
and GFR were compared with measured KRU and GFR (using
urinary urea and creatinine clearances) in the modeling and
validation cohorts using correlation and Bland-Altman
analysis.26 Level of agreement for different cut-off levels1091
Table 1 | Baseline characteristics of patients
Descriptive Modeling group (n [ 191) Validation group (n [ 40) P
Demographics
Age (y) 67 (IQR 53–77) 68 (IQR 50–77) 0.910
Male (%) 69.6 60 0.235
Dry weight (kg) 73.6 (IQR 64.5–88.5) 85.2 (IQR 68.1–96.4) 0.159
Height (cm) 170 (IQR 161–177) 170 (IQR 163–178) 0.698
BMI 25.4 (IQR 22.6–31.1) 27.6 (IQR 23.0–32.3) 0.205
BSA (m2) 1.86 (IQR 1.7–2.0) 1.95 (IQR 1.73–2.11) 0.128
Watson volume (l) 38.7 (IQR 34.2–43.2) 40 (IQR 32.3–46.7) 0.355
Ethnicity (%) 0.106
White 73.3 82.5
Black 8.4 12.5
Asian 15.2 2.5
Other 0.5 2.5
Primary renal disease (%) 0.157
Diabetes 26.7 22.5
Glomerulonephritis 12.6 27.5
Polycystic kidney disease 8.4 12.5
Tubulointerstitial disease 2.6 0
Hypertension or renovascular disease 16.8 15.0
Other 33.0 22.5
Mean weekly systolic BP (mmHg) 150 (IQR 135–162) 152 (IQR 133–171) 0.802
Mean weekly diastolic BP (mmHg) 75 (IQR 66–84) 69 (IQR 63–80) 0.163
KRU (ml/min/1.73 m2) 1.29 (IQR 0–2.38) 0.62 (IQR 0–1.51) 0.042*
Residual GFR (ml/min/1.73 m2) 1.72 (IQR 0–3.51) 0.74 (IQR 0–2.02) 0.016*
Interdialytic urine volume (ml) 675 (0–1510) 295 (IQR 0–865) 0.026*
Anuric patients (%) 34.0 42.5 0.309
Diuretic use (%) 30.9 27.5 0.671
Diuretic dose (milligram of furosemide) 0 (IQR 0–80) 0 (IQR 0–40) 0.714
Dialysis parameters
HDF/high ﬂux HD (%) 82.7/17.3 80/20 0.682
Convective volume (l) 16.7 (IQR 13.1–19.5) 18.2 (IQR 13.4–21.5) 0.191
Ultraﬁltration volume (l) 1.7 (IQR 0.98–2.4) 1.8 (IQR 0.9–2.3) 0.986
Mean IDWG (kg) 1.5 (IQR 0.8–2) 1.3 (IQR 0.7–2) 0.655
Dialysis vintage (y) 1.9 (IQR 0.8–4.8) 2.2 (IQR 0.95–4.35) 0.882
Equilibrated Kt/V (dialyzer) 1.1 (IQR 0.9–1.3) 1.2 (IQR 1.0–1.4) 0.194
Total Kt/V (renal þ dialyzer) 1.3 (IQR 1.2–1.5) 1.4 (IQR 1.2–1.5) 0.914
Co-morbidity
Charlson co-morbidity index 4.0 (IQR 2–5) 3.0 (IQR 2–6) 0.623
Presence of atheromatous disease (%) 49.7 52.5 0.751
Presence of malignant disease (%) 8.9 20.0 0.013*
Presence of diabetes (%) 36.6 25.0 0.159
CRP (mg/l) 6 (IQR 5.0–13.0) 10 (IQR 5.0-20.8) 0.019*
bTP (mg/l) 6.51 (IQR 5.34–9.35) 6.86 (IQR 5.86–7.71) 0.909
b2M (mg/l) 24.3 (IQR 19.2–29.1) 24.4 (IQR 20.3–28.4) 0.645
BMI, body mass index (calculated from dry weight); BP, blood pressure; BSA, body surface area (calculated from dry weight); bTP, b-trace protein; b2M, b2-microglobulin; CRP,
C-reactive protein; GFR, glomerular ﬁltration rate; HD, hemodialysis; HDF, hemodiaﬁltration; IDWG, interdialytic weight gain; IQR, interquartile range; KRU, residual urea
clearance.
Atheromatous disease indicates the presence of any of the following: coronary artery disease, cerebrovascular disease, renovascular disease and peripheral vascular disease.
Diuretic dose is give as milligrams of furosemide. Anuric patients are patients with interdialytic urine volume < 200 ml.
*Denotes statistical signiﬁcance (P < 0.05).
c l i n i ca l i nves t iga t i on J Wong et al.: Predicting residual kidney functionof residual kidney function was assessed using the kappa
statistic (k).
Estimated and measured values of both parameters
correlated signiﬁcantly in both modeling (correlation
coefﬁcients for KRU and GFR were 0.781 and 0.801, respec-
tively [P < 0.001]) and validation cohorts (correlation coef-
ﬁcient for KRU and GFR were 0.783 and 0.762, respectively
[P < 0.001]). Mean bias between measured and estimated
KRU in the validation cohort was –0.50 ml/min [95% CI
–0.25 to –0.75] with 95% limits of agreement from –2.03 to
1.04 ml/min. For GFR, mean bias was –0.64 ml/min [95% CI
–0.89 to –0.39] with 95% limits of agreement from –2.84 to
1.57 ml/min (Figure 1).1092Level of agreement using the kappa statistic (k)27
between the proportions of patients with measured and
predicted levels of GFR above cut-offs in the range 1 to
3 ml/min/1.73 m2 was substantial in the modeling cohort
(k ¼ 0.65–0.67, all P < 0.001) and ranged from moderate
to substantial in the validation cohort (k ¼ 0.43–0.77, all
P < 0.01). Similarly, level of agreement for KRU above
cut-offs in the range 1 to 3 ml/min/1.73 m2 was moderate
to substantial in the modeling cohort (k ¼ 0.51–0.66, all
P < 0.001) and fair to substantial in the validation cohort
(k ¼ 0.36–0.65, all P < 0.02). For both GFR and KRU,
the level of agreements deteriorated outside of these
ranges.Kidney International (2016) 89, 1090–1098
Table 2 | Determinants of bTP: univariable and multivariable regression analysis (R2 of multivariable model [ 0.552)
Determinant
Univariable model Multivariable model
Beta Standard error Signiﬁcance Beta Standard error Signiﬁcance
Demographic/
Clinical data
Age (y) –0.041 0.013 0.001* –0.036 0.009 <0.001
Dry weight (kg) –0.019 0.01 0.069
Post HD weight (kg) –0.018 0.01 0.081
Height (cm) 0.003 0.018 0.886
BMI (kg/m2) –0.041 0.024 0.087
Male gender 0.610 0.427 0.155 1.394 0.326 <0.001
BSA (m2) –1.217 0.831 0.145 –2.205 0.627 <0.001
Watson volume (ml) –0.00001 0 0.671
Ethnicity (white) –1.77 0.427 <0.001*
Systolic BP (mmHg) –0.002 0.009 0.806
Diastolic BP (mmHg) 0.001 0.013 0.932
GFR (ml/min/1.73 m2) –0.813 0.066 <0.001* –0.8 0.061 <0.001
KRU (ml/min/1.73 m2) –1.208 0.1 <0.001*
Comorbidities
CCI –0.14 0.09 0.124
Atheromatous disease 0.959 0.389 0.015* 0.857 0.283 0.003
Diabetes mellitus –0.072 0.41 0.861
Malignancy –1.835 0.68 0.008*
CRP –0.011 0.011 0.35
Diuretic use –1.484 0.413 <0.001*
Diuretic dose –0.002 0.002 0.179
Dialysis parameters
HD Modality (HDF/high-ﬂux HD) 0.559 0.521 0.285 0.896 0.353 0.012
Vintage (y) 0.035 0.026 0.168
UF volume (l) 0.001 <0.001 <0.001*
Convective volume (l) 0.024 0.027 0.359
Dialyser Kt/V 2.462 0.74 0.001*
Mean IDWG (kg) 0.948 0.224 <0.001*
BMI, body mass index; BP, blood pressure; BSA, body surface area; bTP, b-trace protein; CCI, Charlson comorbidity index; CRP, C-reactive protein; GFR, glomerular ﬁltration rate;
HD, hemodialysis; HDF, hemodiaﬁltration; IDWG, interdialytic weight gain; KRU, residual urea clearance; UF, ultraﬁltration volume.
The diuretic dose is given in milligrams furosemide.
*Denotes statistical signiﬁcance (P < 0.05).
J Wong et al.: Predicting residual kidney function c l i n i ca l i nves t iga t ionApplication of predictive equations for KRU and GFR to
KDOQI incremental hemodialysis algorithm
The diagnostic accuracy of predictive equations to identify
those with KRU >2 ml/min/1.73 m2, which might allow safe
reduction of minimum dialysis Kt/V targets as suggested in the
KDOQI Hemodialysis Adequacy guidelines, was assessed in
modeling and validation groups. Receiving operator charac-
teristic analyses were performed for prediction of various cut-
off levels of measured GFR or KRU using the prediction
equations in both the modeling and validation cohorts. The
prediction equations demonstrated a high degree of accuracy
with area under curve values between 0.900 and 0.948 (Table 5).
For instance, identifying patients in the modeling cohort with
measured levels of KRU >2 ml/min/1.73 m2, using cut-off
predicted KRU levels >2 ml/min/1.73 m2 yielded an area un-
der curve of 0.903, a sensitivity of 58%, and a speciﬁcity 92%,
while in the validation cohort corresponding values were area
under curve 0.948, sensitivity 71%, and speciﬁcity 94%.
Using our modeled equation for estimating KRU, we
determined the proportion of patients whose minimum target
Kt/V could be safely reduced according to KDOQI Hemodi-
alysis Adequacy guidelines.4 In the modeling cohort, estimated
levels of KRU >2 ml/min/1.73 m2 correctly identiﬁed patients
with measured values above and below this cut-off level inKidney International (2016) 89, 1090–109881.2% subjects. In 13.6% of the cohort, KRU was falsely esti-
mated to be less than 2 ml/min/1.73 m2 (false negative) and
falsely estimated to be greater than 2 ml/min/1.73 m2
(false positive) in 5.2%. Among false positives, the mean
underestimate between measured KRU and the critical cut-off
level of 2 ml/min/1.73 m2 was 0.75 ml/min/1.73 m2 (range
0.04–2 ml/min/1.73 m2). If target standardized Kt/V had been
reduced from 1.2 to 0.9 for these patients in accordance with
KDOQI guidance,4,28 this would have resulted in underdialysis
equivalent to a mean of 0.11 standardized Kt/V units (range
0.01–0.29). However, 94.8% of patients would have received
doses of dialysis at or above target.
In the validation cohort, patients with KRU >2 ml/min/
1.73m2were correctly identiﬁed in 90% of cases. False-positive
rate was 5%. Of these, mean underestimation between
measured KRU and the critical cut-off level of 2 ml/min/
1.73 m2 was 0.73 ml/min/1.73 m2. Applying KDOQI guidance
would have resulted in underdialysis in these patients by amean
of 0.11 standardized Kt/V units, though 95% of the cohort
would have received a dialysis dose at or above target.
DISCUSSION
bTP has been proposed as a suitable marker of GFR because
its extra renal interference is said to be minimal.10,11,14 We1093
Table 3 | Determinants of b2M: univariable and multivariable regression analysis (R2 of multivariable model [ 0.484)
Determinant
Univariable model Multivariable model
Beta Standard error Signiﬁcance Beta Standard error Signiﬁcance
Demographic data
Age (y) –0.063 0.037 0.088
Dry weight (kg) –0.059 0.029 0.044*
Post HD weight (kg) –0.058 0.029 0.045*
Height (cm) –0.021 0.052 0.688
BMI (kg/m2) –0.118 0.068 0.085
Male gender –2.43 1.223 0.048*
BSA (m2) –4.363 2.383 0.069
Watson volume (ml) 0 0 0.079
Race, Caucasian –2.412 1.272 0.059
Systolic BP (mmHg) –0.013 0.026 0.616
Diastolic BP (mmHg) 0.04 0.039 0.303
GFR (ml/min/1.73 m2) –2.403 0.184 <0.001* –2.36 0.183 <0.001
KRU (ml/min/1.73 m2) –3.476 0.287 <0.001*
Comorbidities
CCI –0.339 0.261 0.195
Atheromatous disease 1.178 1.133 0.3
Diabetes mellitus 3.103 1.157 0.008* –2.031 0.849 0.018*
Malignancy 0.129 1.995 0.949
CRP 0.001 0.033 0.976
Diuretic use –4.425 1.187 <0.001*
Diuretic dose –0.004 0.005 0.417
Dialysis parameters
HD modality (high-ﬂux HD/HDF) –0.597 1.502 0.691
Vintage (y) 0.16 0.073 0.03*
UF volume (l) 0.002 0.001 0.003*
Convective volume (l) 0.126 0.076 0.101
Dialyzer Kt/V 9.413 2.08 <0.001*
Mean IDWG (kg) 1.78 0.663 0.008*
BMI, body mass index; BP, blood pressure; BSA, body surface area; b2M, b2-microglobulin; CCI, Charlson comorbidity index; CRP, C-reactive protein; GFR, glomerular ﬁltration
rate; HD, hemodialysis; HDF, hemodiaﬁltration; IDWG, interdialytic weight gain; KRU, residual urea clearance; UF, ultraﬁltration volume.
The diuretic dose is given in milligrams furosemide.
*Denotes statistical signiﬁcance (P < 0.05).
c l i n i ca l i nves t iga t i on J Wong et al.: Predicting residual kidney functionfound, though, that age, gender, body surface area, presence
of atheromatous disease, and HD modality were independent
determinants of bTP. Prevalence of atheromatous disease and
male gender were positively related, and use of HDF inversely
related consistent with previous reports.9,29 For b2M, we
found an association only with RKF and diabetic status.
Although b2M clearance is superior in HDF, HD modality
was not an independent determinant of serum b2M
levels.17,20 The high prevalence of signiﬁcant RKF in this
cohort, a more important determinant of b2M levels than
even convective clearance, may be a factor.20
Predictive equations for GFR and KRU correlated well with
measured GFR and KRU. The integrated discrimination
improvement index demonstrated superior diagnostic ability
when both bTP and b2M were incorporated into regression
models. The best constructed regression equation using both
biomarkers could explain 63% and 70% of KRU and GFR
variance, respectively; however, a substantial amount of
variation still remains unexplained. Mean bias between
measured and estimated parameters of RKF was –0.5 ml/min
for KRU and –0.64 ml/min for GFR, with wide limits of
agreement. Our ﬁndings suggest that equations incorporating
serum levels of bTP and b2M may not be accurate enough to
estimate GFR if RKF were to be used to calculate minimum
HD targets as advocated by Gotch30 and Casino and1094Lopez.5,28,31 KDOQI guidelines propose an alternative, rela-
tively simple approach for including RKF into HD prescrip-
tion. This conﬁnes attempts to reduce dialysis dose to patients
with a KRU of 2 ml/min/1.73 m2 or more, assuming RKF to
be absent below this.4 We have examined whether equations
incorporating bTP and b2M could be used to accurately
distinguish patients with KRU >2 ml/min/1.73 m2, thus
allowing safe implementation of the KDOQI algorithm.
Applying our modeled equations to estimate KRU at cut-off
>2 ml/min/1.73 m2 in the validation cohort demonstrated
substantial agreement with measured KRU (k ¼ 0.654). Our
modeled equations incorrectly estimated KRU to be $2 ml/
min/1.73 m2 in 5.0% to 5.2% of patients, suggesting that only a
small proportion of patients would receive underdialysis if
KRU estimates were used to set minimum dialysis Kt/V targets
according to the KDOQI algorithm.
There were a number of limitations to our study. The
number of patients in validation cohorts was relatively small
(n ¼ 40). Modeled equations based on a small sample size
may limit applicability to the general population because
other co-morbid factors, such as inﬂammation, active lupus,
and malignancy, may affect levels of bTP9 and b2M.21,22
Similarly, the modeled regression equations were based on a
relatively homogenous population with a high proportion
treated with HDF. Our ﬁndings may not apply to otherKidney International (2016) 89, 1090–1098
Table 4 | Linear regression equations for KRU and GFR
Model
Biomarker
used Parameters b coefﬁcient Signiﬁcance R2
KRU bTP 1/bTP 14.985 <0.001 0.569
1/creatinine 682.73 <0.001
1/urea 11.421 0.03
Male gender 0.521 0.001
b2M 1/ b2M 50.022 <0.001 0.597
1/creatinine 596.149 <0.001
1/urea –14.618 0.004
Caucasian
ethnicity
0.483 0.003
bTP and b2M 1/bTP 9.097 <0.001 0.625
1/b2M 37.568 <0.001
Caucasian
ethnicity
0.402 0.01
GFR bTP 1/bTP 23.968 <0.001 0.633
1/creatinine 1230.716 <0.001
Age –0.016 0.019
Gender 0.938 <0.001
b2M 1/b2M 78.247 <0.001 0.665
1/creatinine 1143.816 <0.001
1/urea –20.4 0.003
Caucasian
ethnicity
0.469 0.033
bTP and b2M 1/bTP 13.471 <0.001 0.700
1/b2M 52.379 <0.001
1/creatinine 782.909 <0.001
Male gender 0.519 0.012
bTP, b-trace protein; b2M, b2-microglobulin; GFR, glomerular ﬁltration rate; KRU,
residual urea clearance.
J Wong et al.: Predicting residual kidney function c l i n i ca l i nves t iga t ionpatient cohorts of different ethnic mix, body composition,
and HDF prevalence. We have used the arithmetic mean of
pre- and post-levels of urea and creatinine because this is a
commonly used method for calculating GFR and KRU. It
does, however, risk potential inaccuracies related to the
non-linear interdialytic increments of both urine excretion
and the plasma solute levels.
bTP and b2M measurements were carried out using
nephelometric and turbidimetric techniques, respectively.
Alternative methods are available for both proteins,32,33 and
variation between different assays may therefore limit appli-
cability of our equations. Additionally, although the precision
of both assays seems robust in non-uremic serum, we cannot
exclude the potential interference of the assay by toxins
related to advanced uremia or the dialysis procedure;Figure 1 | Bland-Altman analysis of measured versus estimated resid
validation cohort (dotted lines represent mean bias with 95% limits o
of mean bias).
Kidney International (2016) 89, 1090–1098however, the manufacturer does not preclude reporting of
these analytes in uremic samples. Both bTP and b2M are
removed during high-ﬂux HD and HDF, and the concen-
trations of both increase during the interdialytic period. b2M
levels exceed 95% of predialysis levels 44 hours after session
end.13 It is likely, therefore, that the predialysis levels after the
long interdialytic gap will equal or exceed the previous pre-
dialysis value. We know of no comparable data for bTP, but,
by the same logic, the level after the long gap is likely to be the
most indicative of peak levels. Hence levels of these bio-
markers immediately before the ﬁrst dialysis of the week are
likely to be the most suitable for predicting RKF. Levels at
other times may overestimate RKF. The levels of both these
parameters will also vary according to the volume status of
these patients but to a lesser extent.
Serial b2M levels increase with declining RKF,34 and
though there are no comparable data for bTP, a similar
relationship would be expected. However, our modeled
prediction equations were developed using b2M, bTP, and
RKF measurements at a single time point. Hence the equa-
tions may not perform similarly in predicting progressive loss
of RKF from serial levels as would be the case if there were
differences in the relative rates of change of B2M and bTP
levels with progressive loss of RKF. Further work is required
to examine this issue before clinical application of our ﬁnd-
ings. Finally, measurement of GFR using interdialytic urine
collections may be prone to error, and ideally the regression
equations should be validated against a gold-standard method
of GFR measurement such as 125I-iothalamate or chromium-51
labeled ethylenediamine tetraacetic acid. However, these
techniques are impractical for routine clinical use, and the
primary objective of this investigation was to determine
whether equations involving bTP and/or b2M could replace
standard measurements of GFR and KRU using interdialytic
urine collections.
In summary, serum levels of bTP and b2M are reasonable
indicators of RKF. Inclusion of both into regression equations
can provide a better estimate of RKF than either molecule
alone. However, serum levels of bTP and b2M may not be
accurate enough to replace the standard estimation of GFR
using urea and creatinine clearances for HD units practicing
an incremental HD regime, although the predictive equations
using bTP and b2M could potentially be used to identifyual urea clearance (KRU) and glomerular ﬁltration rate (GFR) in
f agreement, and hashed lines represent 95% conﬁdence interval
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Table 5 | Receiver operating characteristic analyses for identiﬁcation of patients with RKF above deﬁned levels
Population
RKF measure
(ml/min/1.73 m2) n
Cut-off RKF level to be identiﬁed
(ml/min/1.73 m2 of GFR or
KRU as appropriate) AUC P
Sensitivity at predicted
cutoff (%)
Speciﬁcity at predicted
cutoff (%)
Modeling GFR 114 >1 0.909 <0.001 94 69
89 >2 0.908 <0.001 76 88
58 >3 0.941 <0.001 72 92
42 >4 0.937 <0.001 55 97
22 >5 0.930 <0.001 59 97
KRU 104 >1 0.906 <0.001 88 78
62 >2 0.903 <0.001 58 92
32 >3 0.900 <0.001 50 96
10 >4 0.930 <0.001 30 99
Validation GFR 17 >1 0.903 <0.001 94 52
10 >2 0.910 <0.001 70 77
4 >3 0.944 0.004 100 94
KRU 14 >1 0.942 <0.001 100 69
7 >2 0.948 <0.001 71 94
AUC, area under curve; GFR, glomerular ﬁltration rate; KRU, residual urea clearance, RKF, residual kidney function.
In these receiving operator characteristic analyses, the cut-off level of measured GFR or KRU to be identiﬁed is shown in column 2. Identiﬁcation of patients with GFR/KRU
above these levels is with predicted KRU/GFR from equations (1) and (2) above this same level.
c l i n i ca l i nves t iga t i on J Wong et al.: Predicting residual kidney functionthose with KRU > 2 ml/min/1.73 m2 to follow the suggested
KDOQI incremental HD algorithm. Validation of this
approach in larger, more diverse cohorts of patients is
required.
MATERIALS AND METHOD
Ethical approval
The study was approved by the East Midlands National Research
Ethics Committee. Informed consent was obtained from all studied
patients.
Overall study design
This is a single-center cross-sectional study of prevalent patients
undergoing outpatient HD at the East & North Hertfordshire NHS
Trust. The center deploys an incremental approach to dialysis
prescription involving monthly urine collections while patients
continue to pass urine. Around 80% are treated by HDF, the
remainder using high-ﬂux HD. All were clinically stable at the time
of the study. Patients with positive HIV status and active hepatitis
infection were excluded. Two hundred thirty-one patients (n ¼ 231)
were recruited. Recruitment was carried out prospectively to ensure
that around two thirds of the total cohort had RKF. Patients who
produced less than 200 ml of urine volume over the interdialytic
period were considered to have no RKF—clearances were not
measured in these patients. Of the total cohort, 191 were randomly
assigned to the modeling group for derivation of the predictive
equations and the remaining 40 were assigned to the validation
group.
bTP, b2M, KRU, and GFR, calculated from the mean urea and
creatinine clearance, were measured in all patients. Demographic,
clinical, and dialysis data including age, gender, Charlson
co-morbidity index, dialysis modality, Kt/V, and C-reactive protein
were also collected.
Measurement of residual kidney function: mean urea and
creatinine clearance
Blood was sampled at the end of the ﬁrst dialysis session of the week
and immediately before the next session. Between these samples,
urine was collected over the whole interdialytic period. GFR was1096estimated as mean of the urea and creatinine clearances. These
clearances were calculated using the formula:
Clearanceðml=minÞ ¼ 2$ðUID$VIDÞ
tID$

CpostHD1 þ CpreHD2

Where UID ¼ urinary concentration, VID ¼ urine volume, tID ¼
collection duration, CpostHD1 ¼ plasma concentration at the end of
the ﬁrst dialysis session, and CpreHD2 ¼ plasma concentrations is the
plasma concentration immediately before the start of the second
dialysis session. Post-dialysis urea and creatinine measurements were
adjusted for rebound using the Smye formula35 in accordance with
the European Best Practice Hemodialysis guidelines.5
Measurement of serum b-trace protein and b2-microglobulin
Blood samples for serum bTP and b2M were taken pre-dialysis
immediately before the ﬁrst HD session of the week. Serum bTP
was measured with particle-enhanced immune-nephelometric assay
(N Latex bTP assay; Siemens Diagnostics, Newark, DE, USA), and
serum b2M was measured using by immune-turbidimetric analysis
(Olympus AU640; Beckman-Coulter, Brea, CA). Manufacturer-
supplied data showed that coefﬁcient of variation for bTP and
b2M assays were <6.1% and <10%, respectively.36,37 As judged by
external quality assessment, coefﬁcient of variation for the b2M assay
during the period of study was 3.9% at a mean concentration of 3
mg/L and 4.5% at a mean concentration of 6.6 mg/L. For bTP, co-
efﬁcient of variation was 3.8% at a mean concentration of 0.826 mg/
L and 2.6% at a mean concentration of 12.4 mg/L.
Statistical analysis
Data are reported as medians with interquartile ranges (IQR).
Comparisons between groups were made using the Mann-Whitney
U test. For categorical data, the chi-square test was used to assess
group differences.
Determining independent predictors of bTP and b2M
Linear regression analysis was used to identify signiﬁcant
determinants of bTP and b2M. Potentially signiﬁcant
demographic, clinical, and dialysis parameters were entered into
the regression model to determine the most signiﬁcant predictorsKidney International (2016) 89, 1090–1098
J Wong et al.: Predicting residual kidney function c l i n i ca l i nves t iga t ionof the dependent variable (bTP or b2M) in univariable and
multivariable analyses. Variables with a signiﬁcance level <0.05
were considered signiﬁcant.
Construction and validation of prediction equations to
estimate parameters of RKF
Prediction equations for KRU and GFR based on bTP alone, b2M
alone, and both biomarkers together along with relevant covariates
were constructed using linear regression modeling. Independent
variables were examined for multi-collinearity. All independent
variables had a variance inﬂation factor <3, suggesting minimal
collinearity in the regression models. Residual plots were inspected
for normality and homoscedasticity. The Integrated Discrimination
Improvement index25 was used to assess the predictive accuracy of
the equation that incorporated both biomarkers over the best model
using a single protein for cut-off levels 1 to 5 ml/min for both KRU
and GFR. To assess for potential overﬁtting of regression models for
estimated GFR and KRU, leave-out one cross validation was applied
to the entire cohort (modeling plus validation) to calculate pseudo-R2
for the predictive equations.
Evaluation of predictive equations for KRU and GFR
Correlation was between measured and estimated (from equations)
for KRU and GFR using Spearman’s correlation coefﬁcient. Bland-
Altman26 analysis was used to compare measured and estimated
KRU and GFR in the validation cohort. Level of agreement between
measured and predicted KRU and GFR at different cut-off levels was
assessed using the kappa statistic.27 Receiving operator characteristic
analysis was performed for prediction of various cut-off levels of
measured GFR and KRU using prediction equations in both
modeling and validation cohorts.
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